OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09. Februar 2024 07:00 ET
|
OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
31. Januar 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
08. Januar 2024 07:00 ET
|
OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
05. Januar 2024 09:30 ET
|
OKYO Pharma LTD
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
04. Dezember 2023 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
31. Oktober 2023 07:00 ET
|
OKYO Pharma LTD
Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667...
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
09. Oktober 2023 07:00 ET
|
OKYO Pharma LTD
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
05. Oktober 2023 07:00 ET
|
OKYO Pharma LTD
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the...
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
15. September 2023 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
14. September 2023 09:15 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...